Literature DB >> 16777692

Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia.

Benedito A Carneiro1, William G Watkin, Uday K Mehta, Bruce E Brockstein.   

Abstract

Basal cell carcinoma (BCC) is usually a benign and indolent cancer cured in greater than 95 percent of cases. Nevertheless, it can be locally destructive or occasionally metastasize to distant organs. We report a case of BCC metastatic to the lungs, occurring 17 years after the primary BCC was noticed, that responded to carboplatin and paclitaxel on 3 occasions. The patient also developed pure red cell aplasia (PRCA). Work-up did not reveal underlying thymoma or infectious, rheumatologic, or lymphoproliferative disorders. Parvovirus serologies were negative, and antibodies against erythropoetin were not detected. There was no history of exposure to drugs associated with PRCA. Bone marrow biopsy on 2 different occasions did not show evidence of myelodysplasia. PRCA may represent an unusual paraneoplastic syndrome associated with BCC as reported with other carcinomas. This is the first report of PRCA associated with metastatic BCC or the drugs carboplatin and paclitaxel, which were used to treat it. The literature on chemotherapy for metastatic BCC is reviewed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16777692     DOI: 10.1080/07357900600705474

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  14 in total

Review 1.  Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics.

Authors:  M Nikanjam; P R Cohen; S Kato; J K Sicklick; R Kurzrock
Journal:  Ann Oncol       Date:  2018-11-01       Impact factor: 32.976

Review 2.  Diagnosis and Management of Basal Cell Carcinoma.

Authors:  Keiji Tanese
Journal:  Curr Treat Options Oncol       Date:  2019-02-11

Review 3.  Basal Cell Carcinoma: A Comprehensive Review of Existing and Emerging Nonsurgical Therapies.

Authors:  Julien Lanoue; Gary Goldenberg
Journal:  J Clin Aesthet Dermatol       Date:  2016-05-01

Review 4.  Basal cell carcinomas: attack of the hedgehog.

Authors:  Ervin H Epstein
Journal:  Nat Rev Cancer       Date:  2008-10       Impact factor: 60.716

5.  Systemic therapy for inoperable and metastatic basal cell cancer.

Authors:  Leslie A Fecher
Journal:  Curr Treat Options Oncol       Date:  2013-06

6.  Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease.

Authors:  Daniela Göppner; Martin Leverkus
Journal:  J Skin Cancer       Date:  2010-12-29

Review 7.  Management of high-risk and advanced basal cell carcinoma.

Authors:  S Puig; A Berrocal
Journal:  Clin Transl Oncol       Date:  2015-02-03       Impact factor: 3.405

Review 8.  Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations.

Authors:  Shalini V Mohan; Anne Lynn S Chang
Journal:  Curr Dermatol Rep       Date:  2014-02-09

Review 9.  Vismodegib: the proof of concept in Basal cell carcinoma.

Authors:  Narjiss Berrada; Siham Lkhoyali; Hind Mrabti; Hassan Errihani
Journal:  Clin Med Insights Oncol       Date:  2014-06-02

Review 10.  Investigational agents in metastatic basal cell carcinoma: focus on vismodegib.

Authors:  Nicolas Batty; Ellen Kossoff; Grace K Dy
Journal:  J Exp Pharmacol       Date:  2012-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.